Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Early Phase 1
1(33.3%)
3Total
N/A(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04020419Early Phase 1Terminated

Natural Berry Extract Treatment of Hemangiomas

Role: lead

NCT04018469Withdrawn

Patterned Electric Dressing Effects on Open Wounds

Role: lead

NCT03248154Not ApplicableWithdrawn

Biofilm Infection in Adults and Children Burn Injury

Role: lead

NCT01598116Completed

A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas

Role: lead

NCT00737321Terminated

Mechanisms Regulating Wound Vascularization

Role: lead

NCT01938066Not ApplicableCompleted

Procellera and Negative Pressure Therapy for Acute Wounds

Role: lead

All 6 trials loaded